Avalo Therapeutics (AVTX) Profit After Tax (2014 - 2026)

Avalo Therapeutics has reported Profit After Tax for 13 years, with the latest figure at -$19.6 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 49.29% year-over-year to -$19.6 million; the trailing twelve-month figure through Mar 2026 stood at -$84.8 million (down 216.17% YoY), and the FY2025 full-year result was -$78.3 million, down 122.89% from the prior year.
• Profit After Tax for Q1 2026 stood at -$19.6 million, down from -$13.8 million in the prior quarter.
• The five-year high for Profit After Tax was $98.5 million in Q2 2024, with the low at -$121.3 million in Q1 2024.
• Historically, Profit After Tax has averaged -$12.1 million across 5 years, with a median of -$13.0 million in 2022.
• The largest YoY upside for Profit After Tax was 1301.79% in 2024 against a maximum downside of 1118.38% in 2024.
• Avalo Therapeutics' Profit After Tax stood at -$9.8 million in 2022, then grew by 16.75% to -$8.2 million in 2023, then sank by 332.65% to -$35.3 million in 2024, then soared by 60.95% to -$13.8 million in 2025, then tumbled by 42.25% to -$19.6 million in 2026.
• The last three Profit After Tax figures came in at -$19.6 million (Q1 2026), -$13.8 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.